Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries United Therapeutic (NQ: UTHR ) 358.53 +0.81 (+0.23%) Streaming Delayed Price Updated: 4:00 PM EDT, Sep 27, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about United Therapeutic < Previous 1 2 3 4 5 6 7 8 9 Next > U.S. Stock: United Therapeutics Corp September 25, 2024 United Therapeutics Corporation develops pharmaceuticals to treat vascular diseases such as pulmonary hypertension and peripheral vascular disease. Via Talk Markets Here's How Much $1000 Invested In United Therapeutics 5 Years Ago Would Be Worth Today September 24, 2024 Via Benzinga United Therapeutics to Feature Clinical Data Across its Commercial and Development Portfolio at the CHEST 2024 Annual Meeting September 24, 2024 From United Therapeutics Corporation Via Business Wire Key Takeaways From United Therapeutics Analyst Ratings September 23, 2024 Via Benzinga United Therapeutics Publishes its 2024 Corporate Responsibility and Public Benefit Report Highlighting its Progress Toward a Future Where No Patient Gets Left Behind—Ever September 10, 2024 From United Therapeutics Corporation Via Business Wire The Analyst Verdict: United Therapeutics In The Eyes Of 8 Experts August 20, 2024 Via Benzinga $100 Invested In This Stock 10 Years Ago Would Be Worth $400 Today August 05, 2024 Via Benzinga FDA Battles Backlog of Drug Factory Inspections Since COVID-19 September 06, 2024 FDA faces inspection backlog with serious public health implications, as critical drug manufacturing plants remain unchecked. Via Benzinga Exposures Product Safety Keros Therapeutics Stock Meets 80-Plus RS Rating Benchmark September 05, 2024 Building your watch list, look for stocks with an 80-plus RS Rating. Keros Therapeutics stock just met that criteria with a new score of 86. Via Investor's Business Daily Innovative Drugmaker Roivant Puts Up Really Healthy Sales Numbers August 29, 2024 Roivant stock has an outstanding A- Accumulation/Distribution Rating, showing that institutions such as mutual funds are fairly heavy buyers. Via Investor's Business Daily Ambarella To Rally Around 61%? Here Are 10 Top Analyst Forecasts For Wednesday August 28, 2024 Via Benzinga United Therapeutics Corporation to Present at Upcoming Investor Conferences August 28, 2024 From United Therapeutics Corporation Via Business Wire Navigating 9 Analyst Ratings For United Therapeutics July 25, 2024 Via Benzinga Biohaven Stock Earns Relative Strength Rating Upgrade August 21, 2024 Biohaven stock saw a positive improvement to its Relative Strength (RS) Rating on Wednesday, rising from 88 to 91. Via Investor's Business Daily SpringWorks Therapeutics Stock Clears Key Benchmark, Hitting 80-Plus RS Rating August 21, 2024 A Relative Strength Rating upgrade for SpringWorks Therapeutics shows improving technical performance. Via Investor's Business Daily Soviet Code Breaker Jim Simons' Hedge Fund Renaissance Technologies — Ozempic, Wegovy Maker Novo Nordisk Along With Nvidia, Palantir Among Top Holdings August 19, 2024 Renaissance Technologies, the hedge fund founded by legendary mathematician and former NSA code breaker Jim Simons, recently disclosed its latest stock holdings in a 13F filing with the U.S. Securities... Via Benzinga ZIM Integrated Shipping Services Posts Upbeat Earnings, Joins fuboTV, Foghorn Therapeutics And Other Big Stocks Moving Higher On Monday August 19, 2024 Via Benzinga Why Liquidia Stock Just Reversed Its Seven-Day Sprint And Crashed 38% August 19, 2024 The company is hoping to launch a drug that rivals United Therapeutics' Tyvaso DPI. Via Investor's Business Daily Rivian, Chipotle Mexican And Sirius XM Are Among Top 10 Large Cap Losers Last Week (Aug 11-Aug 17): Are The Others In Your Portfolio? August 18, 2024 Ten large-cap stocks were the worst performers last week, with TME, MBLY, RIVN, CMG, LINE, SIRI, HSY, BAX, BR, and UTHR all seeing declines. Via Benzinga NASDAQ:UTHR is a prime example of a stock that offers more than what meets the eye in terms of fundamentals. August 15, 2024 UNITED THERAPEUTICS CORP (NASDAQ:UTHR) is probably undervalued for the fundamentals it is displaying. Via Chartmill 3 Biotech Stocks on Track for 50% Returns (or More) by 2028 August 04, 2024 Investors should consider snapping up these high potential biotech stocks that could return 50% or more by 2028! Via InvestorPlace UTHR Stock Earnings: United Therapeutics Misses EPS, Beats Revenue for Q2 2024 July 31, 2024 UTHR stock results show that United Therapeutics missed analyst estimates for earnings per share but beat on revenue for the second quarter of 2024. Via InvestorPlace United Therapeutics Stock Skids On Mixed Second-Quarter Results July 31, 2024 The company's earnings came in far below expectations, though sales easily beat. Via Investor's Business Daily United Therapeutics Corporation Reports Second Quarter 2024 Financial Results July 31, 2024 From United Therapeutics Corporation Via Business Wire The 3 Best 3D Bioprinting Stocks to Buy Now July 26, 2024 These are three of the best 3D bioprinting stocks to buy as the technology begins to hit its stride in the health care sector. Via InvestorPlace Beam Therapeutics Stock Earns RS Rating Jump To 85 July 24, 2024 On Wednesday, Beam Therapeutics stock now clears the 80 or higher Relative Strength Rating threshold, with a jump from 65 to 85. Via Investor's Business Daily United Therapeutics Corporation to Report Second Quarter 2024 Financial Results Before the Market Opens on Wednesday, July 31, 2024 July 24, 2024 From United Therapeutics Corporation Via Business Wire Here's How Much $1000 Invested In United Therapeutics 5 Years Ago Would Be Worth Today July 22, 2024 Via Benzinga Biotech Arvinas Stock Earns 82 RS Rating July 17, 2024 The Relative Strength (RS) Rating for Arvinas stock entered a new percentile Wednesday, with a rise from 62 to 82. Via Investor's Business Daily Don't overlook NASDAQ:UTHR—it's a hidden gem with strong fundamentals and an attractive price tag. July 17, 2024 Despite its impressive fundamentals, UNITED THERAPEUTICS CORP (NASDAQ:UTHR) remains undervalued. Via Chartmill < Previous 1 2 3 4 5 6 7 8 9 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.